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ABSTRACT
MDC1 is a key mediator of the DNA-damage
response in mammals with several phosphorylation-
dependent protein interaction domains. The
function of its N-terminal forkhead-associated
(FHA) domain remains elusive. Here, we show with
structural, biochemical and cellular data that the
FHA domain mediates phosphorylation-dependent
dimerization of MDC1 in response to DNA damage.
Crystal structures of the FHA domain reveal a
face-to-face dimer with pseudo-dyad symmetry.
We found that the FHA domain recognizes phos-
phothreonine 4 (pT4) at the N-terminus of MDC1
and determined its crystal structure in complex
with a pT4 peptide. Biochemical analysis further
revealed that in the dimer, the FHA domain binds
in trans to pT4 from the other subunit, which
greatly stabilizes the otherwise unstable dimer. We
show that T4 is phosphorylated primarily by ATM
upon DNA damage. MDC1 mutants with the FHA
domain deleted or impaired in its ability to
dimerize formed fewer foci at DNA-damage sites,
but the localization defect was largely rescued by
an artificial dimerization module, suggesting that di-
merization is the primary function of the MDC1 FHA
domain. Our results suggest a novel mechanism for
the regulation of MDC1 function through T4 phos-
phorylation and FHA-mediated dimerization.
INTRODUCTION
Genomic DNA is constantly damaged by assaults from
both exogenous factors (e.g. the ultraviolet components
of sunlight) and endogenous factors (e.g. the free
radicals generated from metabolic intermediates). The
DNA-damage response (DDR) pathways detect and
repair damaged DNA or induce apoptosis if the damage
is too severe to be repaired. Defects in the DDR result in
genome instability and disease (1).
DNA double-strand breaks (DSBs), the most severe
form of DNA lesions, can be induced by genotoxic
agents such as ionizing radiation (IR) and chemo-
therapeutic agents such as camptothecin (CPT) or can
be generated during cellular processes. DSBs are
repaired by two major mechanisms: homologous
recombination (HR) and non-homologous end-joining
(NHEJ) (2). DSBs are rapidly bound by the Ku70/Ku80
heterodimer, recruiting and activating the catalytic
subunit of DNA-dependent protein kinase (DNA-PKcs),
a phosphoinositol-3 like kinase (PIKK), to initiate NHEJ
(3). DSBs are also sensed by the Mre11-Rad50-NBS1
(MRN) complex, which recruits and activates another
PIKK, ataxia-telangiectasia mutated (ATM), in prepar-
ation for HR-mediated repair (4). One key consequence
of ATM activation is the rapid formation of the
S139-phosphorylated histone variant H2AX (g-H2AX)
surrounding DNA-damage sites (5). g-H2AX serves as a
platform for the recruitment and enrichment of many
DDR factors (6,7). Microscopy and chromatin
immunoprecipitation (ChIP) experiments have revealed
that many DDR factors, such as mediator of DNA-
damage checkpoint 1 (MDC1, also known as nuclear
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MRN complex, co-localize with g-H2AX foci that can
extend up to 1–2 megabases on both sides of the
DNA-damage sites (1,6-9).
MDC1 is the master organizer of assembly and main-
tenance of the g-H2AX-decorated chromatin region
(10-15). MDC1-knockout mice present growth retard-
ation, male infertility, immune defects, chromosome in-
stability, defects in DNA repair by HR, radiation
sensitivity and cancer predisposition (16,17). A reduction
or lack of MDC1 expression has been observed in a sig-
niﬁcant subset of breast cancers and lung cancers (18).
MDC1 also participates in mitotic regulation. MDC1
is hyperphosphorylated upon nocodazole treatment,
which activates the spindle assembly checkpoint (14).
More recently, MDC1 was shown to regulate the
metaphase-to-anaphase transition by modulating the
Cdc20-dependent activation of anaphase-promoting
complex through its BRCA1 C terminus domain
(BRCT) domains (19,20).
MDC1 is a large protein (2089 residues) comprising an
N-terminal forkhead-associated (FHA) domain, a
C-terminal tandem-BRCT domain and a long linker
without a known structural domain (Figure 1A) (21).
The tandem-BRCT domain speciﬁcally binds the
C-terminal phosphopeptide of g-H2AX (22,23). The
linker harbors several repetitive sequence motifs: the
serine–aspartic acid–threonine (SDT) repeats, the TQXF
repeats and the proline–serine–threonine (PST)-rich
repeats. The SDT repeats are constitutively phos-
phorylated by casein kinase II at the serine and threonine
residues, and the dual-phospho SDT motif recruits the
MRN complex via both the FHA domain and BRCT
domains of NBS1 (24-29). This interaction is important
for MRN focus formation, DSB repair, the G2/M check-
point and the intra-S-phase checkpoint. The TQXF
repeats are phosphorylated by ATM in response to
DNA damage, inducing a ubiquitination cascade that
involves the E3 ubiquitin ligases RNF8, RNF168,
HECR2 and BRCA1 (30-34). The PST repeats are
implicated in HR and NHEJ repair of DSBs, but the
underlying molecular mechanism remains unknown
(35,36).
FHA domains are a type of phosphothreonine (pT)-
binding domain and mediate many phosphorylation-
dependent events in DDR and cell cycle control (37,38).
Deletion of the FHA domain in MDC1 results in defective
G2/M checkpoint, inefﬁcient DSB repair by sister chro-
matid recombination and reduced apoptosis in response to
IR (11,16,36,39). Overexpression of the FHA and SDT
domains impairs DNA damage-induced nuclear focus for-
mation of several DDR factors (14). The FHA domain of
MDC1 has been suggested to bind phosphopeptides of
CHK2, ATM and the recombinase RAD51 (11,16,39);
however, its function remains elusive (21).
Through structural, biochemical and cellular studies, we
describe here a novel function of the FHA domain in
mediating MDC1 dimerization. The FHA domain
mediates dimerization by asymmetric FHA–FHA inter-
action and by intermolecular binding to phospho-T4
(pT4) in the N-terminal tail of MDC1. We determined
the crystal structures of the FHA domain alone and in
complex with a pT4 phosphopeptide. Additionally, we
demonstrate that T4 is phosphorylated by ATM in
response to DNA damage and that the trans FHA–pT4
interaction is critical for stable dimerization. Dimerization
promotes the formation of MDC1 foci at DNA-damage
sites, and forced dimerization by an unrelated domain has
a similar effect. Our results support a novel mechanism by
which MDC1 function is regulated through T4 phosphor-
ylation and FHA-mediated dimerization.
MATERIALS AND METHODS
Reagents, antibodies and cell lines
The ATM inhibitor KU55993, the DNA-PKcs inhibitor
NU7026 and the topoisomerase I inhibitor CPT were
purchased from Sigma. The FK506 binding protein
(FKBP) bivalent ligand AP20187 was a kind gift from
Ariad Pharmaceuticals. All cancer cell lines were
purchased from ATCC and cultured in high-glucose
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supple-
mented with 10% fetal bovine serum. The purchased
mouse monoclonal antibodies included anti-
hemagglutinin (HA) (Covance), anti-b-actin (AC15,
Sigma), anti-FLAG (Sigma) and anti-g-H2AX
(Millipore). Rabbit polyclonal antibodies against MDC1
were described before (15). Rabbit polyclonal antibodies
against HA and g-H2AX were purchased from Bethyl and
Cell Signaling Technology, respectively. The rabbit poly-
clonal anti-pT4-MDC1 antibody was raised against the
phosphopeptide MED(pT)QAIDWDVEEE and afﬁnity
puriﬁed (Beijing CoWin Biotech).
Plasmids
The mammalian expression constructs pcDNA-MDC1
and its mutants KN3, KC1, KN2, KN2-R58A and
KN2-NGT were previously described (14,15). HA-FKBP
fusions of MDC1 were constructed in the pcDNAH
A2FKBP vector (40). The domain-deletion mutants
MDC1FHA (deletion of residues 1–144) and
MDC1BRCT (deletion of residues 1698–2089) were
prepared using two-step PCR mutagenesis (41). For bac-
terial expression, MDC1 fragments covering residues
27–138 and 2–133 were cloned into a modiﬁed
pET28a(+) plasmid and were expressed as fusions to an
N-terminal six-histidine tag and SMT3 domain
(His-SMT3) (42). Point mutations were generated using
QuikChange (Stratagene). All the expression constructs
were veriﬁed by sequencing. The kinase domain of ATM
(residues 2709–2964) was ampliﬁed by PCR from human
ATM cDNA and subcloned into pGEX-4T, and the
kinase-dead mutant D2870A was generated by
QuikChange.
Immunoprecipitation and immunostaining experiments
Plasmid DNA was transfected into human cancer cells
with FuGene 6 (Roche). Immunoprecipitation, immuno-
blotting and immunostaining were conducted as described
previously (14,15).
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Induced dimerization assays were performed as previously
described (40). Brieﬂy, plasmids encoding HA-FKBP-
MDC1 and its mutants were transfected into Ad293
cells. After 24h, transfectants were selected with
neomycin for 4 days. The cells were mock treated with
0.1% ethanol or treated with 10nM AP20187 for 4h to
induce the dimerization of FKBP. Where indicated, trans-
fectants were treated with 10mM CPT for 1h to induce
DNA damage 3h after adding AP20187. The cells were
ﬁxed and immunostained with anti-HA and anti-g-H2AX
antibodies.
ChIP assay
ChIP assays were performed as described previously
(43,44). Immunoprecipitated DNA was ampliﬁed with
the primers HRChIP.S (50-TCTTCTTCAAGGACGAC
GGCAACT-30) and HRChIP.R (50-TTGTAGTTGTAC
TCCAGCTTGTGC-30) by real-time PCR. The PCR
signal intensity of each ChIP sample was divided by the
signal of corresponding input sample that had the same
I-SceI and AP20187 treatment but was not immunopre-
cipitated. The signal was further normalized to the signal
of the ChIP sample without I-SceI and AP20187 treat-
ment, yielding the fold of enrichment.
Protein expression and puriﬁcation
MDC1 FHA proteins were expressed in Escherichia
coli BL21(DE3) strain (Novagen). Protein expression
was induced with 0.2mM isopropyl b-D-1-
thiogalactopyranoside for 8h at 25 C. The harvested
cells were resuspended in buffer P300 (50mM phosphate
pH 7.6 and 300mM KCl) and disrupted by sonication.
After the cell lysates were clariﬁed, the supernatant was
passed through a 0.45-mm membrane ﬁlter before loading
onto a 5-ml HisTrap column (GE healthcare). The protein
was washed by 20mM imidazole in P300 and eluted by
500mM imidazole in P300. The His-SMT3 tag was
cleaved by ULP1 protease for 30min at room temperature
and removed by passage through a HisTrap column. The
ﬂow-through containing the cleaved target protein was
concentrated and further puriﬁed with a HiLoad 16/60
Superdex 75 column (GE healthcare) equilibrated in
5mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid/KOH (HEPES-K) (pH 7.6) and 100mM KCl.
The T98A MDC1
2–133 mutant protein was expressed at
16 C and puriﬁed with the His-SMT3 tag uncleaved
Figure 1. MDC1 self-associates via its FHA domain. (A) Diagram of MDC1 domain organization. Boundaries are indicated for MDC1 truncation
constructs. (B–D) HA-tagged MDC1 or mutants were co-transfected with FLAG-tagged MDC1 or mutants into Ad293 cells. After 48h, the total cell
lysates were immunoprecipitated with anti-FLAG and/or anti-HA antibodies and immunoblotted with anti-HA and anti-FLAG antibodies. The
whole cell lysates were also blotted against anti-HA and -FLAG antibodies and are shown as the input. (B) Self-association of MDC1 and its FHA
deletion mutant (MDC1FHA) were analyzed by immunoprecipitation (IP) and immunoblotting (IB). (C) Self-association of wild-type MDC1 (WT)
and its truncation mutants KN2, KN3 and KC1. (D) Self-association of KN2 and its mutants R58A and N96A/G97A/T98A (NGT).
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The size exclusion step was conducted in buffer P250
(20mM sodium phosphate pH 7.6 and 250mM NaCl).
The puriﬁed proteins were concentrated using Amicon
Ultra-15 centrifugal ﬁlter units and stored at  80 C. The
molar concentrations of MDC1
27–138 and MDC1
2–133
referred to the monomeric form and were calculated
with extinction coefﬁcients at 280nm of 6990 and
12490M
 1cm
 1, respectively. The phosphopeptide
MED(pT)QAID (pT4-8P) was chemically synthesized,
puriﬁed by HPLC to >99% purity and lyophilized
(Bootech, Shanghai). The amount of peptide was
estimated by weighting. The GST fusions of ATM
(2709–2964) and its kinase-dead mutant D2870A were
puriﬁed with glutathione-Sepharose beads.
In vitro phosphorylation of MDC1 FHA proteins
The puriﬁed MDC1 FHA proteins (4mg) were incubated
in a 20ml reaction containing 0.2ml of 17mg/ml nu-
clear extracts of HeLa cells (NE), 25mM HEPES–Na
(pH 7.6), 50mM KCl, 5mM MgCl2, 0.2mM EGTA,
0.1mM ethylenediaminetetraacetic acid (EDTA), 1mM
dithiothreitol (DTT), 1.0mM adenosine-50-triphosphate
(ATP) and 1mCi
32P-g-ATP for 30min at 30 C. Large-
scale phosphorylation reactions were conducted in
a 30-ml volume containing the same buffer as above,
50–100mg MDC1
2–133 protein, 500ml NE and 1.5mM un-
labeled ATP for 1h. The phosphorylated protein was
further puriﬁed with a HiLoad 16/60 Superdex 75 pg
column in 5mM HEPES–Na (pH 7.6) and 250mM NaCl.
Crystallization and structure determination
MDC1
27–138 crystals were grown using the hanging drop
vapor diffusion method at 20 C by mixing 1ml 20mg/ml
protein in 5mM HEPES–K (pH 7.6) and 100mM KCl
and 1ml of the well solution containing 0.1M HEPES
(pH 7.5) and 20% PEG-3350. Two types of crystals with
different shapes belonging to space groups P212121 and
P21 grew from the same drops in 2–3 days. The P212121
crystals were derivatized in 1mM KAu(CN)2 in the well
solution for 5h. The crystals were cryoprotected in the
well solution plus 15% glycerol and ﬂash frozen in
liquid nitrogen. The native data sets were collected at
the Shanghai Synchrotron Research Facility (SSRF)
beamline BL17U and processed by HKL2000 (45). The
gold derivative data were collected at a wavelength of
1.5418A ˚ using a Rigaku machine and processed by
Denzo and Scalepack (45).
The structure of the MDC1 FHA domain was ﬁrst
solved for the P212121 crystal form by the single isomorph-
ous replacement with anomalous scattering (SIRAS)
method. Heavy atoms were located by SHELXD (46),
and experimental phase calculation and density modiﬁca-
tion were performed in SHARP (47). The structure model
was automatically built with the Autobuild module of
PHENIX (48), followed by several rounds of manual ad-
justment in COOT (49) and reﬁnement in Refmac (50).
The asymmetric unit (ASU) of the P212121 crystal
contains two FHA molecules arranged as an asymmetric
dimer. The P212121 structure was reﬁned to 1.65A ˚
resolution and contains residues 29–133 in both protomers
and 170 water molecules.
The P21 structure was solved by molecular replacement
(MR) in PHASER using a single FHA subunit of the
P212121 structure as a search model (51). The ASU of
the P21 crystal contains one FHA dimer that has virtually
identical protomer structure and dimer arrangement as the
P212121 dimer except for slight conformational variations
at several loop regions. Only the structure of P212121 space
group is illustrated in our ﬁgures. The P21 structure was
reﬁned to 1.8A ˚ and contains residues 29–101, 105–109
and 111–133 in one protomer, residues 29–134 in the
other protomer and 84 water molecules.
Phosphopeptide pT4-8P was dissolved in DMSO and
mixed at a molar ratio of 2:1 with 0.5mg/ml
MDC1
27–138. The complex was concentrated to 19mg/ml
in buffer containing 5mM HEPES–Na (pH 7.6) and
250mM NaCl. For crystallization, 1ml of the protein
solution was mixed with 1ml of the reservoir solution con-
taining 0.1M HEPES–Na (pH 6.6), 0.2M ammonium
acetate and 57% 2-methyl-2,4-pentanediol in sitting
drops. Crystals appeared in 1–2 days at 20 C and were
ﬂash frozen in liquid nitrogen without further treatment.
The crystal belongs to the P3121 space group and contains
one molecule of the MDC1
27–138 and pT4-8P complex in
the ASU. The structure was solved by MR in PHASER
with one FHA monomer structure as search model. The
ﬁnal model was reﬁned to 1.7A ˚ and contains MDC1
residues 27–133, pT4-8P residues 1–8 and 71 water mol-
ecules. The data collection and reﬁnement statistics are
listed in Supplementary Table S1. The structural ﬁgures
were created in PyMOL (52).
Isothermal titration calorimetry
MDC1
27–138 and its mutants R58A and L127R were
exchanged into buffer P150 (20mM sodium phosphate
pH 7.6 and 150mM NaCl) with a Superdex-75 10/300 GL
columnandsupplementedwith1%DMSObeforetitration.
PhosphopeptidepT4-8Pwasdissolvedin100%DMSOand
diluted in P150 to a ﬁnal concentration of 1% DMSO. For
experiments with SMT3-MDC1
2–133-T98A and related
controls, buffer P150 was replaced by P250. Isothermal ti-
trationcalorimetry(ITC)experimentswereperformedwith
an iTC200 microcalorimeter (Microcal Inc.) at 25 C. The
sample cell contained 200ml of 150mM MDC1 FHA or
140mM SMT3-fused MDC1 FHA. Approximately 2mM
of the peptide was injected via a syringe, with 0.4ml for the
ﬁrstinjectionand2mlforthenext19injections.Thedilution
effect was measured by injecting the peptide into the re-
spective buffer plus 1% DMSO. The integrated heat data
after subtracting the dilution effect were analyzed using a
one-set-of-sites model in Origin according to the manufac-
turer’s instructions. The ﬁrst data point was excluded in the
analysis. The binding parameters H (reaction enthalpy
change in cal mol
 1), K (binding constant in M
 1) and n
(bound peptide per FHA) were ﬂoating in the ﬁt. The
binding free energy G and reaction entropy S were
calculated using the relationships G= RTlnK (R=
1.9872cal mol
 1 K
 1, T=298K) and G=H TDS.
The dissociation constant Kd was calculated as 1/K.
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Size exclusion chromatography was carried out with
AKTA Puriﬁer-10 (GE Healthcare). Approximately
0.5mg of each protein (400mM) was loaded in 100mlt o
a Superdex 200 10/300 GL column running in buffer
HEPES–Na pH 7.6 and 200mM NaCl or P250 for the
T98A mutant. The columns were calibrated with thyro-
globulin (669kD), ferritin (440kD), catalase (232kD),
aldolase (158kD), bovine serum albumin (67kD), ovalbu-
min (43kD), chymotrypsinogen (25kD), cytochrome C
(12.4kD) and aprotinin (6.5kD). In subunit exchange
assays, 50nmol of MDC1
2–133 or its variants were mixed
with 50nmol of MDC1
27–138 in 120ml P150 and incubated
for 1h at 37  C before loading onto a Superdex 75 10/300
GL column running in P150.
Analytical ultracentrifugation
The experiments were conducted using a Beckman-
Coulter XL-I analytical ultracentrifuge equipped with a
6-channel centerpiece and a Beckman An-60 Ti rotor.
MDC1
2–133 and pT4-MDC1
2–133 were exchanged into
buffer P150 using a Superdex 75 10/300 GL column.
MDC1
2–133 was mixed in a 1:2 molar ratio with
phosphopeptide pT4-8P dissolved in DMSO. For each
protein, three samples in 80, 40 and 8mM concentrations
were centrifuged at 25000rpm at 25 C for 24h to estab-
lish sedimentation equilibrium. Concentration proﬁles were
measured at 280nm. The protein partial speciﬁc volume
was calculated to be 0.7349cm
3g
 1 for MDC1
2–133 from
its amino acid composition. The solvent density was
estimated to be 1.00596g/ml by SEDNTERP (J. Philo,
http://www.jphilo.mailway.com/default.htm). Global
ﬁtting of the absorbance proﬁles at three protein concen-
trations was performed in SEDPHAT (53), yielding the
dimerization constant Ka. The MDC1
2–133 and
pT4-MDC1
2–133 data were analyzed by a monomer–
dimer equilibrium model. The MDC1
2–133 in the
presence of pT4-8P data were analyzed by a model that
accounts for MDC1
2–133 dimerization and the association
between MDC1
2–133 and pT4-8P. The dissociation
constant of the MDC1 pT4-8P complex was shown to
be 20mM after the ﬁrst round of ﬁtting. This value was
consistent with the ITC value, so it was ﬁxed in the fol-
lowing rounds of ﬁtting. The bottom of the cell, protein
concentration and Ka were ﬂoating in the ﬁtting, whereas
the extinction coefﬁcient and meniscus were ﬁxed. The
covariance matrix approach was employed to estimate
the errors in log(Ka). The log(Ka) value is 5.036±0.144
for MDC1
2–133, 7.456±0.793 for pT4-MDC1
2–133 and
4.789±0.107 for the MDC1
2–133 and pT4-8P complex.
Accession numbers
The atomic coordinates and structure factors have been
deposited in the Protein Data Bank under accession codes
3UMZ for the MDC1
27–138 structure in the P212121 space
group, 3UNM for the MDC1
27–138 structure in the P21
space group and 3UNN for the MDC1
27–138 and pT4-8P
complex structure.
RESULTS
MDC1 self-associates via its FHA domain
We found that FLAG-tagged MDC1 and HA-tagged
MDC1 co-immunoprecipitated (Figure 1B), suggesting
that MDC1 self-associates in vivo. Domain mapping ex-
periments further indicate that the tandem-BRCT domain
is neither required for MDC1 self-association (KN3)
nor involved in self-association (KC1), whereas an
FHA-deletion mutant cannot complex with itself or with
wild-type MDC1 (Figure 1A-C). Moreover, a fragment
KN2 containing the FHA and SDT domain was sufﬁcient
for self-association (Figure 1C-D). These results point to a
key role for the FHA domain in MDC1 self-association.
As FHA domains are often involved in binding pT, we
asked whether any FHA–pT recognition event is involved
in MDC1 self-association. To this end, we made two
mutants of KN2, one with a single alanine mutation at
residue R58 (R58A) and the other with three alanine mu-
tations, at residues N96, G97 and T98 (NGT). These
residues are critical for pT-binding as illustrated in
known FHA–pT complex structures (54), and both of
the mutant proteins failed to self-associate (Figure 1D).
We can conclude that the FHA domain and its pT-binding
ability are essential for MDC1 self-association.
The FHA domain forms a dimer
To reveal how the FHA domain mediates self-association,
we determined the crystal structure of an MDC1 fragment
containing residues 27–138 (MDC1
27–138) in space group
P212121 at 1.65A ˚ resolution and in space group P21 at
1.8A ˚ resolution (Supplementary Table S1). Despite the
different crystal packing environments, the FHA domain
adopts a nearly identical dimeric structure in both crystal
forms (Supplementary Figure S1). The FHA domain
contains eleven strands named b1 through b11, which
are assembled into a twisted b-sandwich with two
b-sheets (Figure 2A). One b-sheet that mediates dimeriza-
tion is composed of six antiparallel strands arranged in the
order b2–b1–b11–b10–b7–b8. The other b-sheet is formed
by ﬁve strands in the order b4–b3–b5–b6–b9, which are
antiparallel to each other except for the peripheral strand
b4, which is parallel to strand b3. The MDC1 FHA struc-
ture is highly similar to other FHA structures (37). For
example, alignment with the CHK2 FHA structure yields
a root mean square deviation (rmsd) of 1.2A ˚ over 65 Ca
pairs (55).
In the FHA dimer, the six-stranded b-sheet of one
subunit packs against its mate face-to-face. The dyad
axis is roughly perpendicular to the direction of strands,
resulting in the two subunits opposite to each other along
the long dimension of the b-sandwich (Figure 2A).
Interestingly, the dyad symmetry is not perfect, leading
to many non-reciprocal interactions at the dimer interface.
The two subunits are related by a 174  rotation along the
pseudo-dyad axis, rather than by a 180  rotation in a
dimer with perfect dyad symmetry. Consequently, when
one subunit of a dimer is aligned to the non-equivalent
subunit of a second dimer, the other subunits would end
3902 Nucleic Acids Research, 2012,Vol.40, No. 9up unaligned with an average Ca displacement of as large
as 5.5A ˚ (Figure 2B).
The two subunits dimerize at three adjacent strands
b10, b11 and b7 with minor contributions from strand
b1 and the b7–b8 loop (Figure 2C), burying a moderate
490A ˚ 2 solvent accessible area per subunit. The hydropho-
bic residues F37, L101, L120, L122, L127 and P104 from
both subunits mediate major intermolecular contacts at
the center of the dimer interface. There are also
hydrogen bonding and water-mediated interactions on
the periphery of the dimer interface. The side chains of
Q129 and Q118 of one subunit are within hydrogen
bonding distance of the side-chain hydroxyl and
backbone carbonyl of S38 of the other subunit but not
vice versa due to asymmetry in the dimer. R102 of one
subunit non-reciprocally contacts the D125 backbone
carbonyl of the other subunit. The asymmetric dimer
interface is identical in two different crystal lattices, con-
ﬁrming it is not a crystal packing artifact (Supplementary
Figure S1).
MDC1
27–138 also forms a dimer in solution, according
to its elution peak in size exclusion column (Figure 2D).
Replacement of L127, a hydrophobic residue at the center
of the dimer interface, to a charged arginine apparently
disassociates the FHA dimer into a monomer (Figure 2D).
This conﬁrms that the observed interface in crystal is re-
sponsible for dimerization in solution.
The FHA domain recognizes pT4 at the N-terminus of
MDC1
The above co-immunoprecipitation experiments with the
R58A and N96A/G97A/T98A mutants implicate an in-
volvement of the FHA–pT interaction in MDC1 dimer-
ization (Figure 1D). It has been documented that the FHA
Figure 2. Dimeric structure of the MDC1 FHA domain. (A) Ribbon representation of the FHA dimer structure in the P212121 space group.
Two orthogonal views are displayed. The pseudo-dyad axis is shown as an ellipse when perpendicular to the paper or as an arrow when in the
paper. The two subunits are colored green and blue. The 11 strands are labeled by numbers, and the N- and C-termini are marked. (B) Alignment of
two dimers by the non-equivalent protomers to the right. The other protomers to the left do not overlap following the alignment, indicating
asymmetry in the dimer arrangement. (C) Interactions at the dimer interface. Protein backbones are shown as tubes, interacting residues as sticks
and hydrogen bonds as dashed lines. Carbon atoms are green in one subunit and blue in the other subunit, oxygen atoms are red and nitrogen atoms
are blue. (D) MDC1
27–138 and its mutants R58A and L127R were analyzed in a Superdex 200 10/300 GL column running in HEPES–Na (pH 7.6)
and 200mM NaCl. Each protein (400mM) was loaded in a 100ml volume. The elution volume of calibration standards are indicated on the top.
Nucleic Acids Research,2012, Vol.40, No. 9 3903domain of the checkpoint kinase CHK2 makes an inter-
molecular interaction with phosphothreonine 68 (pT68) in
its N-terminal tail, mediating CHK2 dimerization and ac-
tivation (40,56). By analogy, we wondered whether the
FHA domain of MDC1 interacts with a pT from the
other molecule in dimer. We noticed that the extreme
N-terminal sequences of MDC1 (1-MEDTQAID-8)
harbor a TQ motif at positions 4–5, in which T4 is a po-
tential phosphorylation site for the PIKK kinases ATM,
ATR and DNA-PKcs. Moreover, the sequences surround-
ing T4 conform to the in vitro selected binding target for
MDC1 FHA domain, particularly at the  3 (M),+1 (Q)
and+3 (I) positions (54). Therefore, we tested whether the
MDC1 FHA domain binds to an N-terminal eight-residue
phosphopeptide MED(pT)QAID (called pT4-8P). ITC
measurements yielded an apparent dissociation constant
Kd of 40±3mM, suggesting that the phosphorylated T4 is
a binding target of MDC1 FHA (Figure 3A).
T4 is phosphorylated in response to DNA damage
Encouraged by the ﬁnding that the MDC1 FHA domain
binds to pT4 in vitro, we asked if T4 is indeed
phosphorylated in cells. We prepared a recombinant
MDC1 fragment containing residues 2–133 (MDC1
2–133)
and phosphorylated MDC1
2–133 with nuclear extracts of
HeLa cells. The phosphorylated MDC1
2–133 protein
appeared as a major single species that migrated
faster than the unphosphorylated protein in native gel
(Figure 3B). With mass spectrometry analysis, we
detected T4 as the only site phosphorylated (data not
shown). Moreover, alanine substitution of T4 largely
blocked phosphorylation of MDC1
2–133 (see below
Figure 5A). These results indicate that MDC1
2–133 is phos-
phorylated by nuclear extracts primarily at the T4 site.
We raised a rabbit polyclonal antibody against a pT4
phosphopeptide containing the N-terminal 14 amino acids
of MDC1. The antibody was speciﬁc to pT4-MDC1, as it
recognized phosphorylated, but not unphosphorylated
MDC1
2–133 protein (Figure 3C). The speciﬁcity of the
anti-pT4-MDC1 antibody was further demonstrated by
its recognition of transiently expressed and endogenous
MDC1 but not the T4A mutant of MDC1 and the
dephosphorylated protein (Figure 3D and E).
T4 was phosphorylated at a background level in transi-
ently expressed MDC1 (Figure 3D) and endogenous
MDC1 (Figure 3E). The level of pT4 signiﬁcantly
increased after CPT treatment in both cases, indicating
that T4 is phosphorylated in response to DNA damage.
T4 is phosphorylated primarily by ATM
The epitope sequence of T4 and its DNA damage-induced
phosphorylation suggest that PIKKs are responsible for
T4 phosphorylation. The ATM inhibitor KU55993 greatly
inhibited the CPT-induced phosphorylation of MDC1 T4
as well as H2AX, whereas the DNA-PKcs inhibitor
NU7026 had a minor effect (Figure 3F). This ﬁnding sug-
gests that ATM is the primary kinase targeting MDC1 T4.
Moreover, a recombinant ATM kinase domain was able
to phosphorylate MDC1
2–133 but not its T4A mutant
in vitro (Figure 3G). The phosphorylation was abolished
if a dead ATM kinase domain was used, indicating that
the activity is speciﬁcally mediated by ATM rather by
other contaminating kinases.
We next examined whether pT4-MDC1 is enriched at
DNA-damage sites. Immunoﬂuorescence staining with
anti-pT4-MDC1 antibody revealed that pT4-MDC1
formed foci that co-localized with g-H2AX foci, after in-
duction of DSBs by CPT, bleomycin, adriamycin or
mitomycin C treatment (Figure 3H and data not
shown). Moreover, the ATM inhibitor KU55993 abol-
ished the formation of CPT-induced g-H2AX and
pT4-MDC1 foci, whereas the DNA-PKcs inhibitor
NU7026 had a minor effect. These results suggest that
pT4-MDC1 is enriched at DNA-damage sites in an
ATM-dependent manner.
Structures of the FHA–pT4 complex
To understand the mechanism of the MDC1 FHA–pT4
interaction, we determined a structure of MDC1
27–138 in
complex with phosphopeptide pT4-8P to 1.7A ˚ resolution
(Figure 4A and Supplementary Figure S2). The MDC1
FHA domain binds the pT4 phosphopeptide at a pocket
composed of loops b3–b4, b4–b5 and b6–b7. The phos-
phate group of pT4 is recognized by multiple hydrogen
bonds from the side chains of S72, K73 and R58 and the
amide nitrogen of K73. In addition, the backbone atoms
of the phosphopeptide form multiple hydrogen bonds to
the side chains of N96 and R58 and the P69 carbonyl
oxygen. These interactions with the phosphate and
peptide backbone would make highly speciﬁc recognition
of pT at position 4. However, the sequences surrounding
pT4 appear to be only weakly recognized. Some speciﬁcity
may be directed to the two acidic residues E2 and D3
preceding pT4, which are within electrostatic interaction
distance of K73 and R58, and to I7, which makes a van
der Waals contact with the side chain of N96. The pT4
peptide binding mode is quite similar to previously
observed binding modes in other structures of FHA–pT
peptide complex (Supplementary Figure S3) (54,55). The
phosphopeptide association induces little conformational
change in the FHA domain, including the pT-binding
pocket (Supplementary Figure S4).
Puzzlingly, pT4-bound MDC1
27–138 did not form a
dimer in crystal like free MDC1
27–138 or present an alter-
native and reasonable dimer interface. The dimer inter-
face, which is rather weak by itself (see below), was
likely disrupted because of crystal packing interaction
(Supplementary Figure S5).
The dimeric FHA domain binds pT4 in trans
Our structural evidence so far cannot distinguish whether
the MDC1 FHA domain binds pT4 from the same (cis
binding) or a different subunit (trans binding) in the
dimer. If the FHA domain binds pT4 in trans, the
subunit association would be stabilized by such intermo-
lecular interactions (Figure 4B). To distinguish the two
FHA–pT4 interaction modes, we measured the dimer dis-
sociation constant Kd via analytic ultracentrifugation sedi-
mentation equilibrium assay (Figure 4C–E). The
T4-phosphorylated MDC1
2–133 dimer (Kd=35nM) was
3904 Nucleic Acids Research, 2012,Vol.40, No. 9260-fold more stable against subunit dissociation than the
unphosphorylated dimer (Kd=9.2mM). The increased
stability was not due to pT association per se, as binding
of an isolated pT4-8P phosphopeptide did not change the
dimer stability (Kd=16mM). These results suggest that
each subunit of MDC1 FHA dimer binds to pT4 from
the other subunit, signiﬁcantly stabilizing the dimer
formation.
To further investigate the mode of FHA–pT4 inter-
action, we examined subunit exchange between the
pT4-MDC1
2–133 homodimer with mutation R58A, which
is defective in pT-binding (Figure 3A), and the MDC1
27–138
homodimer, which contains functional pT-binding
pockets but no pT4. If the FHA–pT4 interaction occurs
in trans, then subunit dissociation and re-association
would lead to the formation of a more stable heterodimer
in which pT4 in the pT4-MDC1
2–133-R58A subunit binds
to the pT-binding pocket of the MDC1
27–138 subunit.
However, if the FHA–pT4 interaction occurs in cis,
then the heterodimer would have a similar stability
as the two homodimers and not be more energetic-
ally favored. Indeed, mixing of pT4-MDC1
2–133-R58A
Figure 3. MDC1 T4 is phosphorylated by ATM in response to DNA damage, and pT4 is recognized by the FHA domain. (A) Microcalorimetric
titration of phosphopeptide pT4-8P into MDC1
27–138, its mutants R58A and L127R, or 20mM sodium phosphate (pH 7.6) and 150mM NaCl
buffer. The heat peaks were integrated, corrected for the ligand dilution effect and ﬁt to a one-set-of-sites binding model. The dissociation constant,
Kd, values are indicated. (B) MDC1
2–133 was phosphorylated by nuclear extracts (NE) of HeLa cells and resolved in a native gel. (C) Afﬁnity puriﬁed
rabbit polyclonal anti-pT4-MDC1 antibody speciﬁcally recognizes phosphorylated MDC1
2–133 but not unphosphorylated MDC1
2–133.( D) pT4 in
transiently expressed MDC1. Empty vector or vectors expressing FLAG-MDC1 or FLAG-MDC1(T4A) were transfected into U2OS cells. The cells
were mock treated or treated with CPT for 1h, followed by immunoprecipitation with anti-FLAG antibody and immunoblotting with anti-FLAG
and anti-pT4-MDC1 antibodies. (E) pT4 in endogenous MDC1. U2OS cells were mock treated or treated with CPT for 1h. The total cell lysates
were immunoprecipitated with anti-MDC1 antibody, treated with or without calf intestine phosphatase (CIP), and blotted with anti-pT4-MDC1 and
anti-MDC1 antibodies. (F) T4 is primarily phosphorylated by ATM. U2OS cells were treated with DMSO, ATM inhibitor KU55993 (10mM),
DNA-PKcs inhibitor NU7026 (10mM) or both KU55993 and NU7026 for 2h before treatment of 0 or 10mM CPT for 1h. The total cell lysates were
resolved in SDS-PAGE and blotted with anti-pT4-MDC1, anti-MDC1, anti-g-H2AX and anti-b-actin antibodies. Endogenous MDC1 presents
multiple isoforms when blotted with anti-MDC1 antibody; only the slowest migrating one was recognized by anti-pT4-MDC1 antibody.
(G) SMT3-MDC1
2–133, but not its T4A mutant, can be phosphorylated in vitro by a recombinant GST-fused kinase domain of ATM
(GST-ATM, residues 2709–2964). GST-ATM-D2870A is a kinase-dead mutant. (H) U2OS cells were treated as in (F) and were immunostained
with anti-pT4-MDC1 (green) and g-H2AX (red). DNA was stained by DAPI (blue).
Nucleic Acids Research,2012, Vol.40, No. 9 3905and MDC1
27–138 yielded predominantly the heterodimer,
which migrated between the two homodimers in size ex-
clusion chromatography (Figure 4F). The symmetric
shape of the elution peak also suggests that the hetero-
dimer is more stable than the two homodimers that have
trailing peaks. The heterodimer formation depends
critically on the presence of pT4 as unphosphorylated
MDC1
2–133 cannot form a stable heterodimer with
MDC1
27–138 (Figure 4G). Finally, wild-type
pT4-MDC1
2–133 and MDC1
27–138 form only a small
amount of heterodimer (Figure 4H). This is reasonable
given that the pT4-MDC1
2–133 homodimer that contains
a pair of trans FHA–pT4 interactions is expected to be
more stable than the pT4-MDC1
2–133/MDC1
27–138
Figure 4. MDC FHA domain binds to pT4 in trans.( A) The monomeric structure of MDC1
27–138 in complex with phosphopeptide pT4-8P. The
phosphopeptide and important ligand-binding residues are shown as sticks and balls and colored red for oxygen, blue for nitrogen, gray for carbon
in the phosphopeptide and green for carbon in the FHA domain. (B) A structural model depicting the trans FHA–pT4 interaction in the FHA dimer.
Dots denote putative positions of residues 9–26. Phosphate groups are shown as spheres. (C–E) Analytic ultracentrifugation sedimentation equilib-
rium analysis of MDC1
2–133(C), MDC1
2–133 in the presence of pT4-8P (D) and pT4-MDC1
2–133(E). The dimer dissociation constants Kd are
indicated. (F–H) Subunit exchange between MDC1
2–133 and MDC1
27–138 homodimers. pT4-MDC1
2–133-R58A (F), MDC1
2–133 (G) and
pT4-MDC1
2–133 (H) were analyzed by a Superdex 75 10/300 GL column in the absence and presence of MDC1
27–138. The fractions were
resolved with SDS-PAGE, and the gels are shown below the elution proﬁles. The same elution proﬁle and gel image of MDC1
27–138 are displayed
in each panel for comparison.
3906 Nucleic Acids Research, 2012,Vol.40, No. 9heterodimer that contains only one trans FHA–pT4 inter-
action. These subunit exchange results further support
that MDC1 FHA domain recognizes pT4 in trans.
The MDC1 FHA domain without pT4 interaction will
still form a dimer if the protein concentration is much
higher than the intrinsic dissociation constant of FHA
domain (Kd=9.2mM). For example, MDC1
27–138 is
dimeric in the size exclusion chromatography experiments
and in crystal because the protein concentration in
these cases is in the submillimolar to millimolar range
(Figure 2). In contrast, endogenous MDC1, which is
expected to have a low concentration in cells, would
adopt a monomeric structure if T4 is not phosphorylated.
Notably, T4 is phosphorylated at a basal level in untreated
cells (Figure 3D–F), which may account for the detection
of dimerization of overexpressed MDC1 without induc-
tion of DNA damage (Figure 1).
T98 is inaccessible for phosphorylation
A very recent study reported that T98 in the FHA domain
can be phosphorylated by ATM and that phospho-T98
(pT98) is bound by the FHA domain, inducing oligomer-
ization of MDC1 (57). However, according to our crystal
structure, the side chain of T98 is totally buried and
should be inaccessible for phosphorylation in a folded
FHA domain (Figure 4A). Indeed, MDC1
27–138 that
lacks the N-terminal tail could not be phosphorylated by
nuclear extracts of HeLa cells (Figure 5A), indicating that
no phosphorylation site is located within the FHA
domain. In the context of SMT3-fused MDC1
2–133,
where the SMT3 tag was used to increase the solubility
of the T98A mutant protein, the phosphorylation level
was reduced  7-fold by the T4A mutation but was un-
changed by the T98A mutation (Figure 5A). These
ﬁndings further support that T4 is the primary phosphor-
ylation site in MDC1
2–133.
The T98A mutation disturbs the FHA structure and the
pT-binding pocket
The T98A mutation was shown to abolish MDC1 oligo-
merization (57). If T98 is not a phosphorylation site, then
how could the T98A mutation affect MDC1 dimerization?
Our structure suggests that T98 is important for the struc-
tural stability of FHA domain and the conformation of
loop b6–b7, which is involved in phosphopeptide inter-
action (Figure 4A). Speciﬁcally, the methyl group of T98
is packed inside the hydrophobic core of FHA domain,
and its hydroxyl group is involved in a hydrogen bond net-
work that connects the side chains of T98, D91 and S94.
We found that recombinant MDC1
2–133 with the T98A
mutation was poorly soluble and needed to be puriﬁed with
a solubility-enhancing SMT3 tag. SMT3-MDC1
2–133-
T98A was also more heterogeneous and larger in size
than wild-type SMT3-MDC1
2–133 in size exclusion chro-
matography (Figure 5B), suggesting that the T98A
mutation affects the folding and solubility of the FHA
domain. Moreover, ITC measurements indicated that
the T98A mutation reduced the binding afﬁnity of
phosphopeptide pT4-8P by 7-fold (Figure 5C). To
increase the solubility of the mutant T98A protein, the
Figure 5. T98 is not a phosphorylation site and the T98A mutation
disturbs the folding and pT-binding of the FHA domain. (A)
Phosphorylation of MDC1 FHA proteins by HeLa cell nuclear
extracts (NE) in the presence of
32P-g-ATP. (B) SMT3-MDC1
2–133
and its T98A mutant were eluted in a Superdex 200 10/300 GL
column and in buffer 20mM sodium phosphate (pH 7.6) and
250mM NaCl. SDS-PAGE gels of the fractions are shown at the
bottom. (C) ITC analysis of SMT3-MDC1
2–133 and its T98A mutant
with phosphopeptide pT4-8P in 20mM sodium phosphate (pH 7.6) and
250mM NaCl.
Nucleic Acids Research,2012, Vol.40, No. 9 3907ITC experiments were conducted in 250mM NaCl, which
also reduced the binding afﬁnity of the wild-type protein
compared to that measured in 150mM NaCl (Figure 3A).
In summary, our data suggest that the T98A mutation
disrupts MDC1 dimerization by affecting the folding
and pT binding of the FHA domain, rather than by
eliminating a pT site.
Dimerization promotes localization of MDC1 at
DNA-damage sites
MDC1 is quickly recruited to DSB sites and forms discrete
foci that co-localize with g-H2AX (10,11,13,15). We asked
whether FHA-mediated dimerization is important for the
formation of MDC1 foci at DSB sites and whether the
dimerization or the FHA domain itself is important. To
modulate dimerization, MDC1 was fused to the
C-terminus of a tandem FKBP tag, which is a monomer
but can be induced to dimerize by the bivalent ligand
AP20187 (40,58,59).
Upon CPT induction of DNA damage, HA-tagged
FKBP-MDC1 efﬁciently formed foci irrespective of
AP21087, suggesting that both the FKBP tag and
AP21087 did not interfere with the behavior of MDC1
(Figure 6A and B). Deleting the tandem-BRCT domain
completely abolished focus formation, which is consistent
with the essential role of this domain in recognizing the
DSB marker g-H2AX (22). The removal of the FHA
domain decreased the fraction of cells with 10 or more
CPT-induced MDC1 foci by approximately half. This
result suggests the FHA domain plays a role in promoting
MDC1 focus formation. Interestingly, the focus formation
of the FHA deletion mutant could be largely restored
by forced dimerization of FKBP with AP20187. This
ﬁnding suggests that the primary role of the FHA
domain is to mediate MDC1 dimerization. Moreover,
when the dimerization was disrupted by three single-site
mutations that interfere with either the intermolecular
FHA–pT4 interaction (T4A and R58A) or FHA–FHA
association (L127R) (Figures 2D, 3A and 6C), the
MDC1 foci formation was also reduced (Figure 6B).
These mutants were better than the FHA deletion
mutant in focus formation, probably because they could
partially dimerize with endogenous wild-type MDC1. The
defective focus formation of these dimerization mutants
could also be compensated for by the forced dimerization
of FKBP.
We also analyzed the recruitment of MDC1 to a deﬁned
DSB by ChIP assays in U2OS cells (Figure 6D). A
DRGFP gene is integrated into the genome of U2OS
cells and contains an I-SceI restriction site that will
generate a single DNA break in the presence of endonucle-
ase I-SceI (60). HA-FKBP-MDC1, but not its BRCT
deletion mutant, was enriched near the I-SceI-induced
DSB sites independent of AP20187 treatment. The FHA
deletion mutant showed reduced enrichment near the
I-SceI site, which could be restored by AP20187 treatment.
The ChIP results agree with the MDC1 immunoﬂuores-
cence results and further suggest the importance of
FHA-mediated dimerization for MDC1 function.
DISCUSSION
In this study, we found a novel function of the MDC1
FHA domain in mediating phosphorylation-dependent di-
merization. The dimerization is mediated by both the
FHA–FHA association and the trans interaction
between the FHA domain of one MDC1 molecule and
the N-terminal pT4 from the other MDC1 molecule in
the dimer. Our results suggest that ATM phosphorylates
the T4 residue of MDC1 in response to DNA damage,
thereby inducing dimerization of the FHA domain and
facilitating localization of MDC1 to DSBs. We present
several lines of evidence to support this new regulation
mechanism of MDC1 function. First, our biochemical
and crystallographic data show that the MDC1 FHA
domain recognizes the N-terminal pT4 phosphopeptide.
Second, the FHA domain is critically dependent on the
trans pT4 interaction for stable dimerization. Third, T4 is
primarily phosphorylated by ATM in response to DNA
damage. Finally, the FHA domain and its dimerization
function are important for optimal MDC1 focus forma-
tion at DNA-damage sites.
Luo and colleagues recently reported that T98 of
MDC1 is phosphorylated by ATM and interacts with
the FHA domain, inducing MDC1 self-association (57).
This result is contradictory to our ﬁnding about the role of
pT4 in mediating MDC1 dimerization. We demonstrate
that T98 is totally buried in the structure and is inaccess-
ible to phosphorylation. The T98A mutation appears to
disrupt MDC1 dimerization by disturbing the folding and
pT binding of the FHA domain, rather than by blocking a
phosphorylation site. The impairment of FHA folding and
solubility may complicate the interpretation of mutational
effects of T98A. Analyses in MDC1-knockout mouse em-
bryonic ﬁbroblasts have shown that the MDC1 T98A
mutant was efﬁciently recruited to DNA-damage sites im-
mediately after damage but was defective in forming
full-sized foci in the late stage (57). Moreover, the T98A
mutant was shown to partially compromise the intra-S-
phase and G2/M checkpoint response after DNA
damage, DNA repair efﬁciency and ATM signaling (57).
We also found that MDC1 dimerization mutants form
fewer foci at DNA-damage sites. FHA-mediated dimeriza-
tion appears to play a role in the maintenance and devel-
opment of MDC1 foci, but the exact molecular
mechanism remains speculative.
MDC1 is a key mediator that recruits many DDR
factors through its multiple protein–protein interaction
modules (21). Dimeric MDC1 may be more efﬁcient at
recruiting downstream DDR factors and at amplifying
and spreading the DNA-damage signal along the chroma-
tin. In particular, the two tandem-BRCT domains in
dimeric MDC1 are separated by approximately 3500
residues and could bridge two g-H2AX molecules
located in distant nucleosomes. Recently, the
tandem-BRCT domain of MDC1 was shown to recruit
MMSET, a methyltransferase for histone H4 lysine 20,
to DSBs (62). The dimeric structure of MDC1 is well
suited to serve as a bivalent linker connecting g-H2AX
and MMSET.
3908 Nucleic Acids Research, 2012,Vol.40, No. 9Figure 6. Dimerization promotes enrichment of MDC1 at DNA-damage sites. (A) HA-FKBP-MDC1, HA-FKBP-MDC1BRCT or
HA-FKBP-MDC1FHA was stably expressed in Ad293 cells. The cells were mock treated or treated with 10mM CPT for 1h, with 10nM
AP20187 for 4h to induce dimerization of FKBP, or with 10nM AP20187 for 4h and 10mM CPT for 1h. Cells were ﬁxed and immuno-stained
with anti-HA (green) and anti-g-H2AX (red). DNA was stained with DAPI (blue). (B) Percentage of cells with 10 or more HA-foci in (A). Average
of three independent experiments±SD. In each treatment, 100–200 cells were counted. (C) The T4A, R58A or L127R mutations disrupt MDC1
dimerization. HA- and FLAG-tagged MDC1 or the indicated mutants were transiently expressed in Ad293 cells for 48h. The total cell lysates were
immunoprecipitated with anti-HA and anti-FLAG antibodies and immunoblotted with anti-HA and anti-FLAG antibodies. (D) ChIP analysis of
MDC1 localization in deﬁned DSBs. HA-FKBP-MDC1, HA-FKBP-MDC1BRCT or HA-FKBP-MDC1FHA was stably expressed in DFGFP
U2OS cells. The cells were transfected with or without an I-SceI expression construct for 24h, treated with 0 or 10nM AP20187, and harvested for
ChIP assays with anti-HA antibody or a control IgG. The input sample prior to immunoprecipitation and the ChIP elutant were ampliﬁed by
real-time PCR using a pair of primers covering a region 190–335bp from the I-SceI cutting site. The signal intensity of the HA or IgG ChIP samples
was ﬁrst divided by the signal intensity of the input samples of same treatment and then normalized to the signal intensity of the ChIP samples
without AP20187 and I-SceI treatment. Average of three measures±SD.
Nucleic Acids Research,2012, Vol.40, No. 9 3909We propose that dimerization is the primary function of
the MDC1 FHA domain because its role in MDC1 focus
formation can largely be replaced by an artiﬁcial dimer-
ization module. Interestingly, the FHA-mediated dimer-
ization appears to be evolutionarily conserved in MDC1
proteins. The FHA domain of Xenopus tropicalis MDC1 is
dimeric in size exclusion chromatography (S. Luo and
K. Ye, unpublished data). Moreover, the sequences of
Xenopus and mammalian MDC1 are highly conserved in
the FHA domain and the N-terminal residues, including
the T4 site, suggesting that FHA- and phosphorylation-
dependent dimerization are conserved in Xenopus MDC1.
Mutator 2 is the putative ortholog of MDC1 in Drosophila
melanogaster (63). We recently found that the Mutator 2
FHA domain forms a stable dimer but lacks a functional
pT-binding pocket, indicating that dimerization, but not
pT-binding, is conserved between Mutator 2 and MDC1
FHA domains (S. Luo and K. Ye, manuscript in
preparation).
In summary, we have discovered a novel function of the
MDC1 FHA domain as a phosphorylation-dependent di-
merization module that facilitates MDC1 localization to
sites of DNA damage. Phosphorylation of MDC1 T4 and
induced MDC1 dimerization could constitute a new layer
of regulation of the DDR.
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